Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03545425 · ClinicalTrials.gov registry record
Fox BioNet Project: LRRK2-002
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 114
- Enrollment target
- 5
- Study locations
NCT03545425: Completed study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT03545425 is a study of Parkinson Disease that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 114 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03545425, a study of Parkinson Disease, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 114 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.
Primary Outcome
Assess the levels of phosphorylated LRRK2 and LRRK2-phosphorylated Rabs, as measures of LRRK2 kinase activity, in PBMCs and neutrophils from LRRK2 PD, idiopathic PD, non-manifesting LRRK2 mutation carriers and healthy controls.
Conditions Studied
Interventions
- PROCEDURE Biofluid samplings
Study Locations (5)
Florida
- Charles E. Schmidt College of Medicine, Florida Atlantic University - Boca Raton
Illinois
- Northwestern University - Chicago
New York
- Columbia University Medical Center - New York
Oregon
- Oregon Health and Sciences University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2020-04-30 |
What the finished NCT03545425 record still lists
NCT03545425 is an observational study that tracks outcomes without assigning an intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Biofluid samplings is the first listed.
NCT03545425 lists 5 locations in 5 states (Florida, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT03545425 about?
NCT03545425 is a clinical study titled "Fox BioNet Project: LRRK2-002". The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.
What is the current status of trial NCT03545425?
This trial is currently completed. The enrollment target is 114 participants. The study started on 2018-05-16. Estimated completion is 2020-04-30.
What conditions does trial NCT03545425 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03545425?
The interventions under investigation include: Biofluid samplings (PROCEDURE).
Who is sponsoring clinical trial NCT03545425?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03545425 being conducted?
This trial has 5 study locations across Florida, Illinois, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03545425's enrollment target sits among peer trials
114 80th of 297 higher than 218 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI